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Summary
Background; S9788 is a triazineaminopiperidine derivative
capable of reversing multidrug resistance (MDR) in vitro. In
preclinical models S9788 was several fold more potent MDR
inhibitor than verapamil or cyclosporine. At P-glycoprotein
(Pgp) blocking concentrations, S9788 appeared to have only
very little toxicity.
Patients and methods: In a two step phase I trial we treated
39 patients with refractory cancer with S9788 and bolus doxo-
rubicin. The steps differed mainly in the S9788 infusion dura-
tion; in the first part 23 patients received the MDR-reversing
drug S9788 over 30 minutes, in the second step of the study 16
patients were administered S9788 over 150 minutes. The doses
of S9788 were escalated in cohorts of three patients up to a
dose level (DL) of 96 mg/m2 on the 30 minutes infusion, and
to 144 mg/m2 on the 150 minutes infusion. The pharmaco-
kinetics of S9788 were determined.
Results: With the 30-minute infusion schedule symptomatic
cardiac arrhythmia were found to be dose limiting. In all
patients at the highest DL transient cardiac repolarization
prolongation with a long QT-interval on ECG was demon-
strated. With the 150-minute administration schedule, S9788
could be escalated up to 144 mg/m2 without subjective toxicity.
However, transient QT prolongation was present in all patients.
A third degree AV-block and a QT increase of about 40%
occurred at the highest DL. Asymptomatic torsade de pointe
(DL 96 mg/m2) was demonstrated on Holter recording in one
patient. Theses repolarization disturbances with QT increase
were considered dose limiting toxicity and the trial was closed.
No arrhythmia related death was noted. Pharmacokinetics
were similar with both infusion schedules with a mean alpha
half life of 11.3 and 13.2 minutes, for the 30-minute and 150-
minute infusion, and a terminal half life of 13.5 and 15 hours,
respectively. QTc prolongation duration appeared to be dose-
dependent.
Conclusions: With the tested infusion schedules, cardiac
toxicity, in particular AV-blocks and QT prolongation, leading
to ventricular arrhythmia and torsade de pointe, are the dose
limiting toxicities of S9788. Our experience together with the
observation of asymptomatic torsade de pointe in two other
phase I trials of S9788 infused over six hours precluded the
further clinical development of S9788.
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Introduction
Tumor cell resistance to chemotherapy is a major cause
of treatment failure. While some tumors are intrinsically
resistant to chemotherapy, in others, resistance is an
acquired phenomenon developing during chemotherapy
[1, 2]. Multidrug resistance (MDR) frequently develops
after initial successful treatment. Recurrent cancer then
also exhibits resistance to structurally different drugs, to
which it was never exposed. Resistance to multiple drugs
may develop through a common molecular mechanism.
MDR is frequently observed after treatment with doxo-
rubicin and other anthracyclines, vinca alkaloids and
epipodophyllotoxins [3]. MDR has also been reported
for paclitaxel, mitomycin-C and trimetrexate. MDR has
been recognized to be associated with increased ex-
pression of P-glycoprotein (Pgp) [4], a transmembrane
protein which functions as an active efflux pump for
cytotoxic agents [2, 5]. Pgp can be found in normal
kidney, liver, colon and lung tissue, as well as in the
bone marrow. In vitro, MDR overexpression can be
reversed pharmacologically, e.g., by cyclosporine and
its analogue PSC 833, verapamil, tamoxifen and other
structurally not related drugs [5-11]. The mechanism of
this interaction is not fully understood. In vivo, sufficient
concentrations of many of these drugs cannot be
achieved without substantial toxicity [12-14], and the
development of new specific MDR-modulating drugs is
warranted [15]. The SDZ compound PSC 833, a deriva-
tive of cyclosporine D without the immunosuppressive
and nephrotoxic properties of its parent compound is
currently undergoing clinical testing [16-18].
Another such a novel agent capable of reversing
MDR is S9788. This triazineaminopiperidine derivative
has no structural similarities to other known MDR-
modulating agents. In vitro, S9788 has been shown to
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effectively reverse MDR-dependent resistance to doxo-
rubicin, vincristine and a variety of cytotoxic drugs [19,
20]. At a concentration of 5 uM it was 2.5-317 times
more potent than verapamil in reversing MDR [21-23].
Efficacy of S9788 in reversing anthracycline resistance
was also shown in vivo in animal models [24]. In a
murine leukemia model resistant to anthracyclines,
intraperitoneal injection of S9788 30 minutes before
administration of doxorubicin resulted in significant
antitumor activity [25]. Similarly, this effect could also
be demonstrated with vincristine with even greater anti-
tumor activity enhancement in the same model. The
exact mechanism of action of S9788 remains unclear, it
is believed to bind to Pgp and to alter intracellular drug
distribution [26].
Based on these observations phase I studies were
initiated using S9788 in different infusion schedules in
association with doxorubicin-chemotherapy [27, 28]. In
a two-step phase I study we evaluated toxicity and toler-
ability of S9788, infused alone, and in association with
doxorubicin over 30 minutes and 150 minutes, respec-
tively.
Table I Dose levels and number of infusions.
Dose level number
/ r T , _ / r r t 2 \(mgim )
30-min infusion S9788
1(8)
2(16)
3(26)
4(40)
5(56)
6(72)
7(96)
Total 30-min infusion
150-min infusion S9788
8(72)
9(96)
10(80)
11 (104)
12(120)
13(144)
Total 150-min infusion
n
1
4
3
3
3
3
6
23
3
3
2
3
3
2
16
Number of infusions
S9788
2
8
6
6
6
6
12
46
3
3
2
3
3
2
16
S9788 + doxo
3
24
36
22
16
14
23
123
17
13
4
21
11
5
71
Total
5
32
42
28
22
20
35
183
20
16
6
24
14
7
87
Patients and methods
Patient selection
Patients with advanced malignancies unresponsive to standard treat-
ment and for which no other established therapy exists, and with
documented progression during the preceding two months were eligi-
ble. Inclusion criteria included a life expectancy of >12 weeks, an
interval since last chemotherapy or radiation > 4 weeks, and discon-
tinuation of any hormono- or immunotherapy for more than two
weeks. Prior doxorubicin exposure was allowed, providing the cumu-
lative dose did not exceed 300 mg/m2. Other eligibility criteria were
age 18-75 years, ECOG PS <2 , adequate hematological (WBC >4.0
x 109/l, hemoglobin 5*10.0 g/dl, platelets 5s 100 x 109/1), hepatic
(ASAT, ALAT, alkaline phosphatase $2.5 x upper limit of normal,
bilirubin $ 125 x upper normal limit), and renal parameters
(creatinine ^ 1.25 x upper normal limit, creatinine clearance ^ 6 0
ml/minute). Concomitant treatment with other potentially MDR
modulating drugs (e.g., verapamil, cyclosporine) was not allowed. All
patients gave written informed consent and the trial was approved by
the participating institutions ethics committees.
Study design
In a first step (Table 1) patients were treated with S9788 as a 30-minute
infusion. In order to evaluate the intrinsic toxicity of the MDR-
reversant S9788 was administered alone on day 1 and 8 To better
compare the tolerance to doxorubicin with and without the MDR
reversant, the patients received a total dose of 20 mg of doxorubicin
alone on day 15, while doxorubicin was administered immediately after
completion of the S9788 infusion over 30 minutes on day 22. Then,
combined treatment was repeated weekly for a minimum of seven
weeks, or until severe toxicity or tumor progression. Because modu-
lation of normal tissue Pgp by S9788 led to increased toxicity of
doxorubicin in animal models while activity was retained with 50% of
the cytotoxic drug dose, a low total dose of doxorubicin was chosen for
its combination with S9788 in humans.
In a second step due to the observation of severe toxicity possibly
related to the concentration peak with the 30-minute schedule, we
evaluated a protracted infusion of S9788 over 150 minutes (DL 8-13).
S9788 was administered alone on day 1, and with doxorubicin on day
8. The doxorubicin was given l.v. bolus over five to 10 minutes, starting
half an hour after the beginning of the S9788 infusion. This treatment
was again repeated weekly for seven weeks, or until severe toxicity or
tumor progression.
The initial dose of S9788 for the 30-minute infusion was chosen
based on 1/10 of the mouse LDj0. Subsequent dose escalation followed
the modified Fibonacci-scheme (Table 1). Seven dose levels were inves-
tigated from 8 mg/m2 up to 96 mg/m2. The administration of S9788 as
a continuous infusion over 150 minutes used the previously defined
acceptable dose of the 30-minute infusion schedule (72 mg/m2) as the
starting dose. Due to cardiac toxicity at the subsequent dose level, an
additional intermediate dose level of 80 mg/m2 was introduced before
again escalating the dose of S9788 up to 144 mg/m2.
S9788 was supplied by Servier International Research Institute
(Courbevoie, France), as a dimethane sulphonate salt solution in 10 ml
vials containing 100 mg S9788. This solution was further diluted in 5%
glucose for intravenous infusion.
Pretrealment and follow-up studies
At baseline, all patients had a complete physical exam, ECG, cardiac
ejection fraction measured by echocardiography or MUGA-scan,
CBC, kidney and liver function tests and adequate imaging of evalu-
able tumor. Physical exam and CBC were repeated weekly, ECG and
blood chemistry every other week and cardiac ejection fraction was
repeated after administration of four doses of doxorubicin. Patients
were evaluated for toxicity weekly and toxicity were graded using the
NCI common toxicity criteria. Tumor response was evaluated every six
weeks. From dose level 6 on, when cardiac arrhythmias were recog-
nized as a potentially severe toxicity, systematic cardiac monitoring
was introduced consisting of an ECG performed before each S9788
infusion and by Holter recording starting approximately 15 minutes
before until about half an hour after each S9788 infusion. In the second
part of the study (150-minute infusion) all patients had peri-infusional
Holter monitoring starting half an hour before the S9788 infusion and
lasting until at least 30 minutes after the infusion end. QT-interval was
measured and corrected for the heart rate (QTc) according to the
Bazett formula: QTc (msec) = QT (msec) x ^/RR }, and a QTc of
> 440 msec, was considered pathological.
Pharmacokinetic studies were performed on day 1 and day 8 during
the first phase of the study evalutating the 30-minute infusion schedule
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Table 2. Patient characteristics. Table 3. Grade II + III non-cardiac toxicity.
Number of patients (n)
Sex
Male
Female
Age
Median
Range
rcnoi iiiiirit.c bidiub
0
1
~f
L
Prior chemotherapy
Number of prior regimens
0
1
2
=53
Prior radiation
Primary tumor
Colorectal
NSCLC
Breast
Uterus and ovary
Other
Evaluable for response
Infusion duration
30 minutes
23
15
8
57
41-77
12
6
J
19
4
5
8
6
8
8
2
i
•
2
2
8
14
60 minutes
16
11
5
53
28-74
4
6
"1
J
15
1
9
2
4
10
8
0
n
u
1
1
6
8
30-min 150-min
Number of Number of
patients (%) patients (%)
Neutropenia 1(4) 3(19)
Anemia 4(17) 7(44)
Nausea and vomiting 3(13) 6(38)
LFT-elevation 3(13) 3(19)
Injection site pain 8(35) 3(21) '
Asthenia 5 4
Somnolence 0 8 (50)
* Two patients with port-a-cath excluded.
Abbreviation: LFT — liver function tests (ASAT, ALAT,
colorectal cancer progressive after one or
chemotherapy regimens.
Toxicities
The treatment was generally well tolerated
Total
number of
patients (%)
4(10)
11(29)
9(23)
6(15)
11(30)
9(23)
8(21)
phosphatase).
more prior
by all pa-
tients (Table 3). No effects on the blood counts were
detectable after the S9788 infusions alone. Following
combined S9788 and doxorubicin infusions mild to mod-
erate hematological toxicity was noted in a few patients
only: grade II neutropenia in one of 23 patients with the
30-minute infusion, grade III neutropenia three of 16
Not stated in three patients.
and on day 1 of 150-minute infusion schedule Venous blood samples
were drawn before, 15 minutes after the beginning and immediately at
the end of the S9788 infusion. Additional samples were drawn one
hour, two, four, six, eight, 12, and 24 hours after the start of the S9788
infusion. The samples were rapidly centrifuged and the plasma frozen
at -20 centigrade. The analysis was performed centrally using a HPLC
assay [29]. Plasma levels were fitted to a two-exponential pharmaco-
kinetic model. The area under the concentration time curve (AUC) was
determined using the linear trapezoidal rule with extrapolation to
infinity using the MicroPharm software.
Results
Patients characteristics
The patients' characteristics are depicted in Table 2. A
total of 39 patients were enrolled in the study. The
median age was 57 and 53 years for the first and second
group, respectively. The median performance status was
1. Twenty-two patients had measurable lesions at study
entry. In the first step of the study 23 patients received a
total of 183 infusions (median six, range 2-21) of S9788
over 30 minutes alone or in association with doxorubi-
cin (Table 1). In the second step, 16 patients were in-
cluded receiving 87 infusions (median six, range 2-12)
of S9788 over 150 minutes alone or with doxorubicin
(Table 1). All patients suffered from advanced malig-
nancy not amenable to curative treatment. The majority
of the patients included were treated for metastatic
patients receiving the 150-minute infusion. Grade II ane-
mia (< 10 g/1) in a four of 23 and seven of 16 patients,
respectively was attributable to the underlying malig-
nant disease. Blood transfusions were not required. No
thrombocytopenia was observed. Elevated liver function
tests (^ grade II) were found in six patients and are
likely related to the primary disease. No elevation of the
bilirubin was noted and no increase in the creatinine was
observed. Grade III vomiting was observed in two pa-
tients receiving 72 mg/m2 and 96 mg/m2 of S9788 alone
over 30 minutes in the absence of antiemetic prophylaxis.
Nausea and vomiting were reported for 24 episodes in 11
patients receiving the 150-minute infusion, the intensity
was not related to the S9788 dose.
Other toxicities scored as imputable to S9788 admin-
istration over 30 minutes were pain at the injection site
in nine patients, tinnitus in two patients, altered color
vision in two patients and thoracic pain in two patients.
With the 150-minute infusion of S9788 pain at the injec-
tion site was reported in 34 cycles and in nine of the 14
patients treated by peripheral i.v. Further were noted
somnolence in II patients (24 episodes) and malaise or
vertigo during 11 infusions in five patients treated at
doses ^96 mg/m2.
Cardiac toxicity
30-Minute infusion ofS9788
Pretreatment ECGs were available in all patients. Seven
dose levels with a 30 minute-infusion were explored. QT
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Table 4. Arrhythmia and symptoms associated with a 30-minute
S9788 infusion.
Table 5. QT-prolongation during the 150-minute S9788 administra-
tion.
Patient Dose Day Holter records
number level
Clinical
symptoms
QTc AQTc
(msec) {%)
17
18
19
22
21
22
23
AV block I Malaise 540
Bradycardia 50/min
Bradycardja47/min 548
Bradycardia 48/min Malaise 474
Junctional rhythm
Bradycardia 53/min - 488
Junctional rhythm
Bradycardia 52/min - 480
Junctional rhythm
AV block I Somnolence 518
Bradycardia 50/min
AV block I Malaise
Nausea
Somnolence
AV block II Malaise
(Wenkebach) Vomiting
Bradycardia 35/min Anxiety
582
501
38
17
18
17
30
40
25
prolongation and arrhythmias were analyzed by Holter
monitoring from DL 6 (72 mg/m2) on. One patient
treated at DL 6 (72 mg/m2) and three of the six patients
treated at DL 7 (96 mg/m2) developed symptomatic
cardiac arrhythmia (Table 4). Patients complained of
vagal reaction, the systolic blood pressure temporarily
dropped below 100 mmHg, and the Holter records
showed QT-prolongation. Four patients developed bra-
dycardia (35-53 beats/min.) during six drug-infusions.
In three patients it was associated with a prolongation of
the PQ-interval (two patients) or a second degree
AV-block (type Wenckebach, one patient). One patient
developed bradycardia and a junctional escape rhythm
during three of the four S9788-infusions. All ECG-
changes normalized rapidly after the end of the S9788
infusion. These conduction disturbances associated with
symptoms in three of six patients at the DL 7 (96 mg/m2)
were considered dose limiting toxicity, and accrual to
the 30 minutes schedule was stopped.
150-minute infusion ofS9788
Baseline ECG was normal in all patients. A total of six
dose levels with 87 infusions were explored. At dose level
9 (96 mg/m2) one patient developed torsade de pointe,
documented by Holter-monitoring. The patient remained
asymptomatic. However, it was then decided, to de-
escalate to 80 mg/m2 and to subsequently reconsider
dose escalation.
Asymptomatic arrhythmia were documented by Hol-
ter-monitoring in two of the sixteen patients treated with
a 150-minute infusion of S9788. A torsade de pointe was
observed at 96 mg/m2 and a bigeminy in one patient
at 104 mg/m2. One patient treated at 144 mg/m2 devel-
oped a third degree AV-block. None of these patients
experienced any subjective complaints.
Dose level
(mg/m2)
Number of
patients
Mean QTc max
(msec)/(range)
Mean AQTc
(%)/(range)
72-80
96-104
120
144
491 (439-546)
526 (458-577)
494 (487-502)
562 (557-568)
24(13-37)
28(16-42)
23(19-29)
42 (39-44)
In all but two patients, a decrease in the heart rate
during the infusion was observed. Bradycardia (<60
beats/min) was documented in six patients for 27 of 70
evaluable courses (39%). However the heart rate dropped
below 50 beats/minute in only two patients.
Prolongation of the QT-interval was documented at
all dose levels. At doses of ^ 120 mg/m2 QT-prolonga-
tion was present in all patients (Table 5). Large inter-
individual variations of QT-prolongation were observed
and a dose 144 mg/m2 S9788 was considered the MTD
since both patients had QTc values > 550 msec corre-
sponding to a 39% and 44% increase of the basal values.
This condition known to favor torsade de pointe or
ventricular arrhythmias was considered the dose limit-
ing toxicity and the study was closed.
We specifically analyzed whether the patients expe-
riencing cardiac arrhythmias had a history of cardiovas-
cular disease or electrolyte laboratory abnormalities.
None of these patients had previously known cardiac
disease or hypertension. Baseline ECG was normal in
all patients. Of the patients experiencing cardiac dys-
function, four patients (two patients in each study) had
grade 1 hypokalemia. The other electrolytes (sodium,
potassium, chloride, calcium, phorphorus) were within
normal limits. The patient developing a torsade de pointe
has been treated with hydrochlorthiazide/amiloride for
over a year because of peripheral edema. No other pa-
tient received vasoactive drugs or drugs known to pro-
long the QT-interval.
Reversibility of QTc prolongation
Prolongation of the QT-interval (>440 msec) was ob-
served at all dose levels. When corrected for the heart
rate, no definitive correlation between dose level and
QTc-interval could be demonstrated. The QTc was ana-
lyzed in 76 Holter-ECG 60 minutes after starting S9788.
The median QTc-value was 494 msec, and the mean 505.
QTc values over 600 msec were measured in one patient
at dose level 6 (72 mg/m2) and 7 (96 mg/m2) of the 30-
minute infusion, and in one patient at dose level 9
(96 mg/m2 over a 150-minute infusion). All observed
arrhythmias and ECG changes were fully reversible and
normalized usually within less then 12 hours after dis-
continuing the S9788 infusion.
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Torsade de pointe
In one patient asymptomatic torsade de pointe occurred
during the second week of treatment, whose case is
described in detail:
This 64 year old obese woman was diagnosed five
years earlier with adenocarcinoma of the rectum,
stage Dukes C. She was initially treated by surgery
and adjuvant radiotherapy and an isolated liver metas-
tasis was resected 11 months later. A second resection
of a liver metastasis and a loco-regional recurrence
was performed four years after diagnosis, followed by
chemotherapy with 5-FU and leucovorin. The patient
progressed after 6 cycles of chemotherapy and enroll-
ment in this trial with S9788 and doxorubicin was
suggested. Her past medical history was unremark-
able; for mild-moderate peripheral edema she has
been taking daily hydrochlorthiazide 50 mg/amiloride
2.5 mg for over one year. Baseline cardiac evaluation
by echocardiography showed a normal left ventricular
function without signs of hypertrophy or dilatation.
Laboratory evaluation was unremarkable with a so-
dium 138 mmol/1, a potassium 3.5 mmol/1, a calcium
of 2.28 mmol/1 and phosphor of 0.8 mmol/1. Magne-
sium was not done. The ECG showed an unremark-
able sinus rhythm with normal QT-interval. A total
dose of 170 mg S9788 (DL 9: 96 mg/m2) was admin-
istered over 150 minutes on day 1, and on day 8 in
association with doxorubicin (20 mg). At the end of
S9788 administration on day 1 QT-prolongation was
documented by ECG. The QTc-interval before the
first S9788 administration was 430 msec, at the end
of the infusion 470 msec, Holter monitoring revealed
rapid normalization of the QT-interval and no signifi-
cant arrhythmias. On day 8, baseline QTc-interval
was 438 msec (Figure la), at the end of the infusion
590 msec (Figure lb). Ten minutes after the end of the
S9788 perfusion (about two hours after doxorubicin
administration), an isolated episode (duration < 10
seconds) of torsade de pointe was registered on
Holter-monitoring (Figure lc). The patient remained
asymptomatic. Electrolytes drawn before the infusion
were unremarkable with a sodium of 139 mmol/1,
potassium 3.7 mmol/1, chloride 100 mmol/1, calcium
2.49 mmol/1 and phosphor 1.1 mmol/1. On follow-up
the Holter ECG and subsequent ECG's were again
normal. The patient died of disease progression three
months later.
Maximum tolerated dose
With both administration schedules arrhythmia was dose
limiting. Both, on ECG and Holter monitoring, QT-
prolongation, ventricular tachycardia and torsade de
pointe were the predominant findings. With the shorter
infusion schedule patients experienced malaise and tem-
porarily blood pressure drop, The protracted S9788 in-
fusion over 150 minutes induced ventricular tachycardia
and torsade de pointe without any noticeable symptoms.
UASTCAU1A lUt- UOhM gT-i71—
Figure I. EKG changes and torsade de pointes during S9788 30-
minute infusion, (a) EKG before S9788: heart rate 50/min, QTc-time
438 msec, (b) EKG at the end of S9788 infusion: heart rate 54/min,
QTc-time 590 msec, (c) Holter during S9788: torsade de pointes initiated
by a short-long-short sequence.
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Figure 2. AUCco versus dose. S9788 30-minute infusion: AUC extrapo-
lated to infinity (|iM * h) versus dose level (mg/m2) during cycle 1.
We consider a dose of 96 mg/m2 of S9788 as the MTD
for a 30 minute infusion schedule, and 144 mg/m2 for a
150 minutes infusion duration, the recommended doses
for phase II evaluation are 72 mg/m2 as a 30-minute
infusion and 104 mg/m2 as a 150-minute infusion.
Responses
Twenty-two patients were evaluable for response. One
partial remission in the lung was achieved with the 30-
minute infusion schedule in a woman with breast cancer
with bone and pulmonary metastases. This patient had
previously received hormonotherapy. Immediately prior
to inclusion in this trial she had progressed after two
cycles of losoxantrone (DuP 941) treatment. No objec-
tive responses were observed in the other patients.
Pharmacokinetics
The results of the pharmacokinetic studies are here
briefly summarized. [30, 31] In 16 patients receiving a
30-minute infusion of S9788 pharmacokinetic sampling
was performed on day 1 (n = 16) and day 8 (n - 14).
Maximal plasma levels measured ranged from 0.05-4.85
uM and linearly correlated with the dose administered.
Plasma levels >0.5 uM were achieved at a doses >26
mg/m2. A linear correlation was also demonstrated for
the AUC versus the administered dose level (r = 0.84,
Figure 2). Fitted to the bicompartment model the esti-
mated half life alpha was 11.3 minutes (± 12.8), and the
terminal half life of 13.5 hours (± 11.8). Plasma levels
were available for all 16 patients on day 1 treated with a
150-minute infusion. Peak concentrations were achieved
after 120-150 minutes and ranged from 0.1 uM - 1.5 uM
with a large intersubject variability (Figure 3). Mean
alpha half live was 13.2 minutes (± 8.4), and terminal
half live 15.0 hours (±9.6). In eight patients the plasma
concentrations of S9788 could be correlated to the QTc-
time (Figure 4). The QTc prolongation duration ap-
peared to be dose-dependent (Figure 5).
I
0*1
16
TOn>(h)
Figure 3. Plasma concentrations S9788. S9788 I50-minute infusion:
plasma concentrations (uM) after escalating doses of S9788 during
cycle I.
Discussion
Intrinsic and acquired multidrug resistance remains a
major impediment for successful treatment with anti-
cancer agents. One approach to overcome MDR is the
modulation of Pgp. Several drugs have been recognized
in vitro and in vivo to interfere with Pgp-function. Cal-
cium channel blockers like verapamil are able to reverse
MDR by competitive inhibition of Pgp. However, at the
clinically effective doses, cardiovascular toxicity with
hypotension and congestive heart failure limits their
clinical applicability [12]. Steroid derivatives like tamox-
ifen and megestrol are also known for their ability to
revert multiple drug resistance. In two trials with vin-
blastine high doses of tamoxifen (up to 150 mg/m2 twice
daily) have been administered. Observed toxicities,
although not considered dose limiting, consisted of
tremor, hyperreflexia, dizziness and asymptomatic QT-
prolongation on ECG [32, 33]. Cyclosporine A has also
been extensively investigated in the clinic for Pgp-modu-
lation [34-36]. With a 60-hour continuous infusion a
clinical effect could be demonstrated with increased
etoposide [35, 36] and doxorubicin [34] exposure and
increased toxicity, mainly myelosuppression, nausea and
vomiting and hyperbilirubinemia [35, 36]. Currently, a
new and nonimmunosuppressive cyclosporine analogue
is undergoing clinical testing [17]. In a phase I trial in
association with etoposide severe ataxia was the DLT
and other common toxicities were paraesthesiae, hyper-
bilirubinemia and myelosuppression [17].
In order to specifically reverse MDR and modulate
Pgp the triazinoaminopiperidine derivative S9788 was
developed by Servier Research Laboratories. In vitro
and in vivo preclinical models showed promising activity
in reversing the Pgp-function with very little toxicity. In
vitro, S9788 was more active than verapamil and showed
similar activity with cyclosporine. In the mouse model
DLT was neurological with clonic seizures. Beagle dogs
presented with moderate ataxia and seizures at high and
very high doses (7.2 mg/kg and 14.5 mg/kg, respec-
tively). After the observation of conduction abnormal-
ities during the phase I study, new in vivo testing in
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Figure 4. Plasma concentrations and QTc-prolongation. S9788 150-minute infusion: plasma concentrations and QTc-prolongation versus time in
individual patients at different dose levels.
anesthetized dogs was performed. Administration of
S9788 at 10 mg/kg bradycardia, conduction blocks and
prolongation of the QT-interval were demonstrated.
Similarly to verapamil S9788 may inhibit the calcium
channels, although its affinity is 20 times lower than
verapamil. However, in a model with isolated rat Purkinje
fibers S9788 also inhibits rapid sodium influx and thus
diminishes the contractility of the myocardium. This
sodium channel block is possibly the cause for the con-
duction abnormalities and the susceptibility to arrhyth-
mia observed.
We evaluated toxicity of weekly S9788 administration
on two different administration schedules. Dose limiting
toxicity was reached with a 30-minute administration
duration at 96 mg/m2, and at 144 mg/m2 when S9788
was infused over 150 minutes. With both administration
schedules DLTs were cardiac arrhythmia with QT-pro-
longation, AV conduction blocks, premature beats and
torsade de pointe. Symptomatic arrhythmia were only
observed with the shorter infusion schedule. Vagal type
malaise were reported in three of six patients treated at
the highest DL (96 mg/m2) of the 30-minute infusion.
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Figure 5 QTc-prolongation versus dose. S9788 150-minute infusion:
duration of QTc-prolongation over 480 and 550 msec, respectively in
function of the total dose of S9788 administered.
With the 150-minute infusion schedule QT-prolonga-
tion, bigeminy and torsade de pointe were demonstrated
on ECG and Holter-24-hour cardiac monitoring, but
none of the patients was symptomatic. While carefully
analyzing the data, no correlation of cardiac susceptibil-
ity, prior cardiovascular disease, concomitant vasoactive
medication or electrolyte disturbances was evident. All
observed cardiac abnormalities were rapidly reversible
after S9788 discontinuation.
Torsade de pointe describes a syndrome of ventricu-
lar tachycardia with polymorphic oscillations in the
QRS-height in association with lengthening of the QT-
interval of usually more than 500 msec [37]. The tachy-
cardia occurs due to early afterdepolarizations and may
result in ventricular fibrillation. Hypokalemia and hypo-
magnesemia may be a predisposing factors. Prolonga-
tion of the QT-interval has also been recognized as a
rare familial disorder frequently leading to ventricular
arrhythmias and sudden death [38, 39]. Acquired QT-
prolongation has been described in association with
several drugs, like class IA and class III antiarrhythmics
(quinidine, procainamide, disopyramide, sotalol, amio-
darone), phenothiazines, tricyclic antidepressants and
nonsedating antihistamines such as terfenadine [40]. In
the current trial we observed one episode of torsade de
pointe and ventricular tachycardia during the second
S9788 administration over 150 minutes in a 64-year-old
patient with no previous history of cardiac disease. On
the day developing torsade de pointe, the ECG before
the infusion showed sinus bradycardia (50 bpm), but
electrolytes within normal limits on laboratory evalua-
tion.
In two other phase I trials of S9788 with infusion
schedules of 30 minutes and 30 + 150 minutes, QT-
prolongation, AV conduction blocks, ventricular arrhyth-
mias with one episode of torsade de pointe were again
determined as the dose limiting toxicities [27, 41]. In a
similar phase I study with a protracted S9788 adminis-
tration over six hours doses up to 480 mg of S9788 could
be administered. Again QT prolongation was present at
all dose levels. QTc prolongation > 550 msec was docu-
mented during 25% and 29% of courses respectively at a
S9788 dose of 240 and 320 mg, and in 67% and 41% of
courses, at dose levels of 400 and 480 mg, respectively
(Data on file, IRIS, Servier SA, Courbevoie, France). We
treated six patients with a six-hour infusion for a total of
17 cycles at doses of 160, 240 and 320 mg/m2 of S9788
with doxorubicin administration three hours after the
S9788 infusion started. Significant QT-prolongation oc-
curred at all doses. This trial prematurely closed after we
observed another episode of torsade de pointe at a dose
of 240 mg. Ventricular arrhythmias and one torsade de
pointe were also reported in a French trial using a six-
hour infusion [42]. A dose-effect relationship could not
be clearly demonstrated [42]. The pooled data of over
230 patients treated with S9788 on different infusion
schedules show a variable individual susceptibility, with
QT prolongation observed at all dose levels and with all
schedules. A correlation of the administered dose of
S9788 and the extent of QTc-prolongation is suggested.
Despite improved subjective tolerability of S9788 with a
prolonged administration schedule, the risk of severe
arrhythmias persisted with longer infusion durations.
The in vivo measured concentrations correspond to the in
vitro determined concentrations necessary for reversing
MDR (0.5-5 uM). The short first half life may make a
longer infusion duration necessary for a clinically signifi-
cant MDR reversal [8]. In order to limit QTc prolonga-
tion in the majority of patients to < 550 msec, the plasma
concentrations of S9788 should not exceed 0.4 uM. For a
QTc time < 480 msec our model suggests concentrations
^0.3 uM. This contrasts with the required minimally
effective in vitro S9788 concentration which is estimated
at 0.5 uM [43]. Based on these considerations, it was
decided not to pursue the further development of S9788.
Acute cardiac toxicity is unusual in daily oncology
practice. Unlike anthracycline induced cardiomyopathy
or congestive heart failure, S9788 induced conduction
and repolarization disturbances may be considered as
potentially life threatening adverse events. Only prospec-
tive and systematic evaluation for this type of adverse
event is able to detect potentially dangerous changes.
The observed prolongation of the QT-interval with
S9788 predisposes to ventricular arrhythmia and torsade
de pointe. In our trial, the occurrence of severe arrhyth-
mia due to the QT prolongation, modulated by individual
susceptibility, underlying unrecognized cardiac disease,
electrolyte imbalances and other unidentified parame-
ters were considered too unpredictable and potentially
dangerous. The low benefit/risk ratio did not justify
further clinical development of S9788.
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